Dulaglutide common uses, half-life, side effects and more

Dulaglutide is a once-weekly injection for type 2 diabetes. It is approved for blood sugar control in adults and in children from age 10. United States approval also covers reducing the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes who have heart disease or several risk factors for it. It is not approved for obesity or weight management in any country. It comes as a ready-to-use prefilled pen and needs no mixing.

• Type 2 diabetes blood sugar control in adults
• Blood sugar control in children from age 10
• Heart attack and stroke risk reduction in type 2 diabetes
• Modest weight reduction alongside diabetes treatment
• Off-label weight management despite no obesity approval

Once weekly

Adults start at 0.75 mg by subcutaneous injection once weekly. The dose may rise to 1.5 mg after 4 weeks and then in 1.5 mg steps every 4 weeks to a maximum of 4.5 mg weekly. The starting dose is also a legitimate dose to stay on rather than only a stepping stone. European labeling starts people already taking other diabetes drugs at 1.5 mg instead of 0.75 mg. Children from age 10 start at 0.75 mg weekly and may rise once to a maximum of 1.5 mg weekly. That ceiling is a third of the adult one. No obesity dose exists.

• A missed dose can be taken if at least 3 days remain before the next one and should otherwise be skipped
• The weekly dosing day can move as long as 3 days have passed since the last dose
• Dulaglutide and insulin go in as separate injections and must never be mixed
• The pen arrives filled with solution and needs no reconstitution

About 5 days in humans. This supports once-weekly subcutaneous dosing.

Pens are stored in the fridge at 2 to 8 degrees Celsius. A pen may be kept at room temperature up to 30 degrees for a total of 14 days across its whole life rather than 14 days each time it leaves the fridge. Do not freeze it and do not use a pen that has been frozen. Keep the pen in its carton to protect it from light.

• Nausea (12% at 0.75 mg and 21% at 1.5 mg against 5% on placebo)
• Diarrhea, vomiting, and abdominal pain that all climb with dose
• Decreased appetite, indigestion, and fatigue
• Injection-site reactions that are rare in adults at 0.5% and more common in children at about 4%
• Low blood sugar when combined with insulin or a sulfonylurea
• Gallbladder problems, pancreatitis, and kidney injury from dehydration (all uncommon)

Dulaglutide activates the GLP-1 receptor. That raises glucose-dependent insulin release, lowers glucagon when blood sugar is high, slows stomach emptying, and reduces appetite through brain satiety pathways. It acts at that one receptor alone. Tirzepatide by contrast also acts at the GIP receptor. The molecule is two identical chains held together by disulfide bonds. Each chain carries a GLP-1 lookalike sequence joined to a piece of a human antibody. A single amino acid swap at position 8 blocks the enzyme that destroys natural GLP-1 within about two minutes. The antibody portion makes the whole molecule roughly 63 kilodaltons. That is large enough that the kidneys cannot clear it quickly. It is grown in hamster ovary cell culture rather than built by chemical synthesis.

Human evidence is strong and long-running. REWIND followed 9,901 adults for a median of 5.4 years. Major cardiovascular events occurred in 12.0% on dulaglutide and 13.4% on placebo. The hazard ratio was 0.88. Most participants had cardiovascular risk factors rather than established heart disease. That makes the result substantially a prevention finding. AWARD-11 enrolled 1,842 adults and established the 3 mg and 4.5 mg doses. AWARD-PEDS enrolled 154 young people aged 10 to under 18 and improved blood sugar over 26 weeks with no difference in body mass index. SUSTAIN-7 compared dulaglutide against semaglutide head to head. Semaglutide produced greater reductions in both blood sugar and weight. A later trial of 13,299 people found tirzepatide non-inferior to dulaglutide for cardiovascular events. Weight change across the whole program ran from a small gain on the starting dose to about 4.6 kg lost on the highest dose at 36 weeks. No phase 3 obesity program has ever been run.

• A United States boxed warning covers thyroid C-cell tumors seen in rats and rules out use with a personal or family history of medullary thyroid carcinoma or MEN 2
• Severe or persistent abdominal pain means stopping the drug and being checked for pancreatitis
• People who already have diabetic retinopathy need their eyes monitored because complications ran 8.5% against 6.2% on placebo over five years
• Insulin and sulfonylureas raise the risk of low blood sugar and their doses often need reducing
• Pregnancy and breastfeeding are not recommended and animal studies found malformations and lasting effects in offspring
• Lyophilized powder sold online as dulaglutide cannot be the real drug because the approved product exists only as a solution in prefilled pens